礼来拟收购AtaiBeckley
2026-07-19 14:51:04
据CNBC报道，礼来（Eli Lilly）将以最高38亿美元收购临床阶段迷幻药开发商AtaiBeckley。此次交易显示，大型制药公司正加快布局用于治疗多类心理健康疾病的迷幻药物。AtaiBeckley的核心资产BPL-003是一种5-MeO-DMT合成药物，以鼻喷剂形式用于治疗难治性抑郁症，已获美国食品药品管理局（FDA）突破性疗法认定，当前处于三期临床试验阶段。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
AI Is Destroying The Internet. Math Is Our Only Hope.Next article：
美企内部分歧加剧：抛售超买入11比1
